Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $39.00 Average PT from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have received an average rating of “Moderate Buy” from the five brokerages that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $39.00.

Several equities analysts have recently weighed in on the stock. Truist Financial upped their price objective on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a report on Monday, February 26th. Needham & Company LLC restated a “buy” rating and issued a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Jefferies Financial Group restated a “hold” rating and issued a $37.00 target price (up previously from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Friday, March 29th. Finally, Piper Sandler restated an “overweight” rating and issued a $39.00 target price (up previously from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in the company. SummerHaven Investment Management LLC grew its position in Collegium Pharmaceutical by 1.1% in the 4th quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after purchasing an additional 368 shares in the last quarter. Illinois Municipal Retirement Fund grew its position in Collegium Pharmaceutical by 2.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 19,879 shares of the specialty pharmaceutical company’s stock worth $612,000 after purchasing an additional 411 shares in the last quarter. West Tower Group LLC grew its position in Collegium Pharmaceutical by 101.8% in the 4th quarter. West Tower Group LLC now owns 892 shares of the specialty pharmaceutical company’s stock worth $27,000 after purchasing an additional 450 shares in the last quarter. Maverick Capital Ltd. grew its position in Collegium Pharmaceutical by 5.2% in the 1st quarter. Maverick Capital Ltd. now owns 11,296 shares of the specialty pharmaceutical company’s stock worth $271,000 after purchasing an additional 555 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in Collegium Pharmaceutical by 0.8% in the 3rd quarter. Los Angeles Capital Management LLC now owns 76,876 shares of the specialty pharmaceutical company’s stock worth $1,718,000 after purchasing an additional 585 shares in the last quarter.

Collegium Pharmaceutical Price Performance

COLL stock opened at $34.84 on Friday. The company’s fifty day simple moving average is $36.85 and its 200 day simple moving average is $30.75. Collegium Pharmaceutical has a 12-month low of $20.83 and a 12-month high of $40.95. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of 29.69 and a beta of 1.03. The company has a quick ratio of 1.10, a current ratio of 1.17 and a debt-to-equity ratio of 2.48.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The firm had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. On average, analysts expect that Collegium Pharmaceutical will post 5.63 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.